FDMT: Pivotal global trials advance a disruptive, lifelong gene therapy for retinal disease
4D Molecular Therapeutics, Inc. (FDMT) is progressing pivotal global trials for a gene therapy aimed at treating wet AMD and DME. The company is focusing on broad adoption through competitive pricing and an "always-on" therapy. Strong financials support commercialization efforts, with key data readouts anticipated soon.
5 Best Gene Therapy Stocks to Buy in 2026
The article highlights 4D Molecular Therapeutics Inc (NASDAQ:FDMT) as one of the top gene therapy stocks for 2026, noting its significant stock gains over the past year and analysts' projections for further growth. It details the company's strong financial position with sufficient cash to fund operations into 2028 and its progress in clinical trials, particularly for 4D-150, a therapy targeting blinding retinal vascular diseases. The company is actively developing gene therapies for rare and common diseases in ophthalmology and pulmonology, with key clinical trial data expected in 2027.
About Us
This page from WaterWorld provides the latest news and stock information for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT). It lists recent company announcements, financial results, clinical trial updates for gene therapies, and participation in investor conferences. The content includes details on stock performance and links to various news sources like MarketBeat, GlobeNewswire, and Benzinga.
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics (NASDAQ: FDMT) is experiencing strong Phase 3 momentum for its lead retinal gene therapy, 4D-150, for wet AMD, with rapid patient enrollment. The company also plans to initiate a Phase 3 trial for diabetic macular edema (DME) soon. Key differentiators highlighted include the therapy's durability, which has shown significant reductions in treatment burden and injection-free rates, and a favorable safety profile across over 400 treated patients.
4D Molecular Therapeutics, Inc. - Common Stock (Nasdaq:FDMT) Stock Quote
This article provides a detailed stock quote for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), including its current price, intraday and 52-week ranges, trading volume, and market capitalization. It also features recent news headlines related to the company's clinical trials, financial results, investor conference participation, and employment inducement grants. Key performance metrics like YTD, 1-month, 3-month, 6-month, and 1-year returns are also displayed.
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics (FDMT) is experiencing rapid Phase 3 momentum for its lead retinal gene therapy, 4D-150, for wet AMD and is preparing for a Phase 3 trial in diabetic macular edema. The company highlights strong durability and safety data from prior studies, showing significant reductions in treatment burden and high injection-free rates with no serious adverse events. With multiple upcoming readouts and a healthy cash balance extending into H2 2028, 4D Molecular Therapeutics plans to commercialize 4D-150 in the U.S. independently.
4D Molecular Therapeutics, Inc. - Common Stock (NQ: FDMT
This page provides recent news headlines and financial updates for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). It includes information on employment inducement grants, executive leadership changes, financial results, conference participations, and analyst ratings, alongside discussions of stock performance and clinical trial updates.
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants
BVF (Biotechnology Value Fund) and its affiliates have filed an amended Schedule 13G/A, disclosing their holdings in 4D Molecular Therapeutics (FDMT) as of March 31, 2026. The report details beneficial ownership of 5.35 million shares, alongside 8.48 million pre-funded warrants, although a "Pre-Funded Warrants Blocker" limits exercisable warrants to 2.47 million shares. This filing provides insights into the investment group's significant stake and the constraints on their potential ownership increase in 4D Molecular Therapeutics.
Fat Pitch Financials - 4D Molecular Therapeutics, Inc. - Common Stock (Nasdaq:FDMT) Stock Quote
This article provides a detailed stock quote for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), including its current price, daily range, 52-week range, and shares outstanding. It also compiles recent news headlines related to the company, highlighting announcements regarding clinical trials, financial results, investor conferences, and employment inducement grants. Key performance metrics like year-to-date and 1-year returns are also listed.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 14 new non-executive employees a total of 141,100 Restricted Stock Units (RSUs) on May 12, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing gene therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares
RA Capital Management, L.P. and its affiliates, including RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, have filed an amended Schedule 13G/A, reporting a beneficial ownership of 9.99% in 4D Molecular Therapeutics (NASDAQ: FDMT), totaling 5,105,622 shares. This ownership includes direct holdings and pre-funded warrants which are subject to a "Beneficial Ownership Blocker" limiting the exercise to prevent exceeding the 9.99% threshold. The filing provides detailed figures on shares and warrants, and clarifies the delegation of voting and dispositive power.
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its board compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees on May 12, 2026. These RSUs were issued under the company’s 2025 Employment Inducement Award Plan in accordance with Nasdaq Rule 5635(c)(4). The company aims to attract and retain talent through these equity grants, continuing its pattern of ongoing hiring and pipeline investment.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 14 new non-executive employees a total of 141,100 Restricted Stock Units (RSUs) on May 12, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing targeted therapeutics, with lead candidates in trials for retinal vascular diseases and cystic fibrosis.
[EFFECT] 4D Molecular Therapeutics, Inc. SEC Filing
This article reports on an SEC Filing (Form EFFECT) by 4D Molecular Therapeutics, Inc. (FDMT), indicating the effectiveness of its S-3 filing on May 13, 2026, at 4:00 P.M. The filing is categorized as neutral in both impact and sentiment. The article also provides an overview of FDMT's stock performance, recent news, and other SEC filings.
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation
Chardan Capital has reiterated its Buy rating for 4D Molecular Therapeutics (FDMT). This indicates continued confidence from the firm in the company's stock performance.
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation
Chardan Capital has reiterated its Buy recommendation for 4D Molecular Therapeutics (FDMT). This indicates a continued positive outlook from the investment firm regarding the company's stock performance. The article implies that analysts are providing updated ratings and price targets for FDMT.
FDMT: 4D-150's phase III progress and robust data position it as a potential game-changer in retinal gene therapy
FDMT's 4D-150 is rapidly advancing in phase III trials for wet AMD and DME, demonstrating strong efficacy and safety, along with the potential to reduce treatment burden. The company plans internal commercialization for the U.S. and is considering global partnerships, with manufacturing on track and a cash runway extending into 2028. This progress positions 4D-150 as a potential game-changer in retinal gene therapy.
State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026
State Street Corporation has filed a Schedule 13G, disclosing a 5.3% passive stake in 4D Molecular Therapeutics Inc. (FDMT), amounting to 2,707,875 shares of common stock as of March 31, 2026. The filing indicates shared voting power of 2,647,452 shares and shared dispositive power of 2,707,875 shares through affiliated investment-adviser entities including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company. This disclosure reflects a standard institutional holding for investment purposes rather than an intention to influence corporate control.
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report
Following 4D Molecular Therapeutics, Inc.'s first-quarter results, analysts significantly increased their revenue forecasts for 2026 to US$15.0m, while also anticipating larger losses per share, projected at US$3.92. Despite these changes, the consensus price target remained unchanged at US$28.22, suggesting that increased forecast losses are not expected to have a long-term impact on valuation. However, the company's expected revenue growth is significantly slower than the wider industry.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
4D Molecular Therapeutics (FDMT) saw its shares rise 7.4% after releasing first-quarter results that exceeded revenue expectations but showed higher-than-forecasted losses per share. Analysts have updated their estimates, increasing 2026 revenue forecasts to US$15.0m but also raising loss per share predictions to US$3.92, indicating a cost associated with achieving growth. Despite these updates, the consensus price target remained unchanged, suggesting that the long-term prospects, rather than immediate earnings, are a key focus for investors.
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report
Following 4D Molecular Therapeutics' first-quarter results, analysts significantly increased their revenue forecasts for 2026 to US$15.0m, while also projecting higher per-share losses of US$3.92. Despite these changes, the consensus price target remained unchanged at US$28.22, suggesting that the anticipated losses are not expected to have a long-term impact on the company's valuation. However, the company's revenue growth is expected to slow considerably and perform worse than the broader industry.
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged
Analyst Matthew Caufield of H.C. Wainwright has reiterated a Buy rating for 4D Molecular Therapeutics, maintaining a $36 price target. This positive outlook is driven by the significant progress in the company's wet AMD gene therapy program, specifically the completion of enrollment in the Phase 3 4FRONT-1 trial and anticipated full enrollment of 4FRONT-2 in 2026. Caufield believes the prior PRISM trial data, showing substantial reductions in treatment burden, will translate positively into the Phase 3 setting, indicating the potential for 4D-150 to revolutionize wet AMD treatment.
4D Molecular Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.62, Implies 178% Upside
The 12-month price target for 4D Molecular Therapeutics, Inc. (FDMT) stock has been revised down slightly to $27.62 from $28.25, based on estimates from 8 analysts. This new target suggests a potential upside of approximately 178% from its May 7 closing price. The consensus rating among 10 analysts remains a "Buy," with 8 Buy ratings and 2 Hold ratings.
Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $33
Goldman Sachs has reiterated its Buy rating on 4D Molecular Therapeutics (FDMT.US) but has lowered its price target to $33. This indicates a continued positive outlook on the company despite a downward adjustment in the expected stock valuation.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its first quarter 2026 financial results, highlighting $458 million in cash, cash equivalents, and marketable securities, projected to fund operations into the second half of 2028. The company announced the completion of enrollment for its 4FRONT-1 trial ahead of schedule and provided updates on its 4D-150 program for wet AMD and DME, with key data readouts expected in 2026 and 2027. Despite an increased net loss compared to Q1 2025, the company emphasized strong operational execution and upcoming milestones across its therapeutic pipeline.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its first-quarter 2026 financial results, highlighting the completion of enrollment for its 4FRONT-1 clinical trial for wet Age-related Macular Degeneration (AMD) and robust cash reserves of $458 million, projected to fund operations into the second half of 2028. The company anticipates several key clinical data readouts in 2026 and 2027 for its 4D-150 program in both wet AMD and Diabetic Macular Edema (DME), alongside plans to initiate a global Phase 3 trial for DME. Financials show an increased net loss and R&D expenses driven by Phase 3 clinical trials, compensated by collaboration revenue from Otsuka.
Wet AMD gene therapy moves ahead; 4DMT targets 2027 Phase 3 data
4D Molecular Therapeutics (4DMT) announced the completion of randomization for its 4D-150 Phase 3 clinical trial in wet Age-related Macular Degeneration (AMD), with topline data expected in the first half of 2027. The company also reported Q1 2026 financial results, including $458 million in cash and equivalents, projected to fund operations into late 2028. Upcoming milestones include further trial enrollments and additional 2-year data readouts for various programs.
4D Molecular (NASDAQ: FDMT) details Q1 loss and cash runway to 2028
4D Molecular Therapeutics reported a Q1 2026 net loss of $68.8 million on $3.0 million in collaboration and license revenue, increasing R&D expenses due to advancing its lead eye disease program. Despite the loss, the company maintains a strong cash position of $458 million, which is expected to fund operations into the second half of 2028. Key clinical milestones include the completion of randomization for the 4FRONT-1 Phase 3 trial for wet AMD and upcoming data readouts for multiple programs.
4D Molecular Therapeutics (NASDAQ: FDMT) files $400M shelf registration
4D Molecular Therapeutics (NASDAQ: FDMT) has filed a shelf registration statement (S-3) to offer up to $400 million in various securities, including common stock, preferred stock, debt securities, warrants, and units. This new registration includes $200 million of unsold securities from a previous filing and adds another $200 million, allowing the company flexibility to raise capital over time. The filing specifies that the exact terms and timing of any future offerings will be detailed in prospectus supplements.
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported its Q1 2026 financial results, highlighting $458 million in cash which is projected to fund operations into the second half of 2028. The company announced significant progress in its clinical trials, including the completion of enrollment for its 4FRONT-1 study for wet AMD and anticipated data readouts for multiple programs in late 2026 and 2027. Despite an increased net loss due to higher R&D expenses for Phase 3 trials, 4DMT continues to advance its therapeutic pipeline for retinal diseases and cystic fibrosis.
4D Molecular Therapeutics (Nasdaq:FDMT) - Stock Analysis
4D Molecular Therapeutics (FDMT) is a late-stage biotechnology company focused on developing gene therapies for retinal vascular diseases and cystic fibrosis, leveraging its proprietary Therapeutic Vector Evolution platform. The company is currently unprofitable but projects significant revenue growth in the coming years, driven by its lead candidate 4D-150 for wet AMD and DME, which has progressed to Phase 3 trials and received RMAT designations. Despite a volatile share price and shareholder dilution, analysts maintain a high price target, believing the company's innovative pipeline and strong cash position offer long-term investment potential.
4DMT to Participate in Upcoming Investor Conferences
This article announces that 4DMT will be participating in upcoming investor conferences, although the specific details of these conferences are not provided. The content is brief and serves solely as a notification of their planned engagements with investors.
4DMT management to present at BofA, RBC healthcare conferences
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its management will participate in two May 2026 healthcare conferences: the BofA Securities 2026 Healthcare Conference on May 13, 2026, and the RBC 2026 Global Healthcare Conference on May 19, 2026. The company's management will present and hold one-on-one investor meetings at both events, with archived webcasts available on their Investors website for up to one year. This provides an opportunity for investors to learn more about the late-stage biotechnology company's progress, including its lead product candidate 4D-150 for blinding retinal vascular diseases.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (FDMT) announced its management will participate in two upcoming investor conferences in May 2026: the BofA Securities 2026 Healthcare Conference and the RBC 2026 Global Healthcare Conference. The company, a late-stage biotechnology firm, will present and hold one-on-one meetings to discuss its durable and disease-targeted therapeutics, including its lead product candidate 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (4DMT) announced that its management will present and participate in one-on-one meetings at two upcoming investor conferences in May: the BofA Securities 2026 Healthcare Conference and the RBC 2026 Global Healthcare Conference. The company will discuss its progress as a late-stage biotechnology firm, focusing on its lead product candidates 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis. Webcasts of the presentations will be available on the 4DMT website.
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (4DMT) announced that its management will present and participate in one-on-one meetings at upcoming investor conferences in May. The company will be featured at the BofA Securities 2026 Healthcare Conference on May 13, 2026, and the RBC 2026 Global Healthcare Conference on May 19, 2026. 4DMT is a late-stage biotechnology company developing therapeutics for conditions like retinal vascular diseases and cystic fibrosis.
4D Molecular Therapeutics | ARS: Annual Report to Security Holders
This document is the Annual Report to Security Holders for 4D Molecular Therapeutics. It likely contains detailed financial statements, operational summaries, and other information relevant to the company's performance over the past year for its shareholders.
4D Molecular Therapeutics | DEFA14A: Others
This article mentions 4D Molecular Therapeutics and a DEFA14A filing related to "Others". The content of the document itself is not provided, making it difficult to extract further details.
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing
This article reports on an ARS SEC filing by 4D Molecular Therapeutics, Inc. (FDMT) on April 28, 2026, at 04:06 PM. The filing is available as a PDF document on SEC EDGAR. The company's stock performance and recent news and filings are also briefly detailed.
Board moves key votes at 4D Molecular Therapeutics (NASDAQ: FDMT) 2026 meeting
4D Molecular Therapeutics (NASDAQ: FDMT) has announced its all-virtual 2026 annual meeting on June 17, 2026, where stockholders will vote on the election of three Class III directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and a non-binding advisory vote on executive compensation. The proxy statement details key figures such as 52,274,735 common shares outstanding and executive compensation, including President and CEO David Kirn, M.D.'s total compensation of over $2 million in 2025. The company also provides information on its corporate governance, director compensation, and related party transactions.
4DMT and Otsuka to advance eye disease treatment in APAC
The article discusses the collaboration between 4DMT and Otsuka to advance eye disease treatments in the Asia-Pacific (APAC) region. This partnership aims to bring new therapeutic options to patients suffering from various ophthalmic conditions in these markets.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on April 14, 2026, its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees. These grants were made under the Company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) has announced employment inducement grants to new employees as required by Nasdaq rules. These grants were approved by the Compensation Committee of the company's Board of Directors and reported on April 15, 2026. The grants, including stock options and restricted stock units, are meant to attract and retain new talent.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company developing therapeutics for diseases like wet age-related macular degeneration and cystic fibrosis.
Five new 4DMT hires receive 67,600 stock units under Nasdaq rule
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its compensation committee granted a total of 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants, made under the company's 2025 Employment Inducement Award Plan and Nasdaq Rule 5635(c)(4), are intended to attract new talent. This action aligns with the company's ongoing hiring and expansion efforts, particularly as it advances its late-stage gene therapy programs.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 67,600 Restricted Stock Units (RSUs) to five new non-executive employees on April 14, 2026. These grants were made under the Company’s 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration and cystic fibrosis.
Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $23
Evercore has reiterated its Buy rating on 4D Molecular Therapeutics (FDMT.US) but has lowered its price target to $23. This adjustment reflects Evercore's updated valuation perspective on the company.
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular
Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,247,151 shares in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT), which represents a 10.3% stake. The Asset Managers within Janus Henderson exercise shared voting and dispositive power over these shares through Managed Portfolios, but disclaim rights to dividends or sale proceeds. The filing highlights institutional ownership and is considered a neutral sentiment update.
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT
JPMorgan Chase & Co. reduced its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 42.2% in the third quarter, now holding 513,515 shares valued at $4.46 million. Despite this reduction, institutional investors collectively own 99.27% of the stock. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $31.25, following a strong earnings beat where the company reported $0.43 EPS against a -$0.53 consensus and $85.09M revenue versus $30.86M expected.
FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for 4D Molecular Therapeutics (FDMT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent Form 8-K filings detailing clinical trial data, collaborations, and executive appointments. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.
